Current Developments in Pharmacogenomics of Multiple Sclerosis

被引：5
|
作者：
Carlson, Rebecca J. [1 ,2 ]
Doucette, J. Ronald [2 ,3 ,4 ]
Nazarali, Adil J. [1 ,4 ,5 ]
机构：
[1] Univ Saskatchewan, Coll Pharm & Nutr, Mol Cell Biol Lab, Saskatoon, SK S7N 5C9, Canada
[2] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5C9, Canada
[3] Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, Saskatoon, SK S7N 5C9, Canada
[4] City Hosp, Cameco Multiple Sclerosis Neurosci Res Ctr, Saskatoon, SK, Canada
[5] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5E2, Canada
来源：
CELLULAR AND MOLECULAR NEUROBIOLOGY | 2014年 / 34卷 / 08期
基金：
加拿大健康研究院;
关键词：
Pharmacogenomics; Multiple sclerosis; Interferon-beta; Glatiramer acetate; SNPs; Genome-wide association studies; INTERFERON-BETA THERAPY; GLATIRAMER ACETATE; GENE; SUSCEPTIBILITY; POLYMORPHISMS; MARKERS;
D O I：
10.1007/s10571-014-0095-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.
引用
收藏
页码：1081 / 1085
页数：5
相关论文
共 50 条
  • [21] Recent Developments in Imaging of Multiple Sclerosis
    Poloni, Guy
    Minagar, Alireza
    Haacke, E. Mark
    Zivadinov, Robert
    NEUROLOGIST, 2011, 17 (04) : 185 - 204
  • [22] Recent developments in multiple sclerosis treatment
    Dagmara Mirowska-Guzel
    Pharmacological Reports, 2010, 62 : 26 - 26
  • [23] Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach
    Vosslamber, Saskia
    van Baarsen, Lisa G. M.
    Verweij, Cornelis L.
    PHARMACOGENOMICS, 2009, 10 (01) : 97 - 108
  • [24] Current immunotherapy in multiple sclerosis
    Bashir, K
    Whitaker, JN
    IMMUNOLOGY AND CELL BIOLOGY, 1998, 76 (01): : 55 - 64
  • [25] Current treatment for multiple sclerosis
    Papeix, Caroline
    Lubetzki, Catherine
    Lyon-Caen, Olivier
    PRESSE MEDICALE, 2010, 39 (03): : 381 - 388
  • [26] Current management of multiple sclerosis
    Leary, SM
    Thompson, AJ
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2000, 54 (03) : 161 - 169
  • [27] Current therapy of multiple sclerosis
    Johnson, KP
    Baringer, JR
    HOSPITAL PRACTICE, 2001, 36 (04): : 21 - +
  • [28] Current knowledge of multiple sclerosis
    Michiels, Yves
    ACTUALITES PHARMACEUTIQUES, 2018, 57 (573): : 24 - 25
  • [29] Current immunotherapy of multiple sclerosis
    Paull, F.
    Ruprechet, K.
    NERVENARZT, 2015, 86 (08): : 1031 - 1042
  • [30] A current understanding of multiple sclerosis
    Shull, Catherine
    Hoyle, Brittany
    Iannotta, Caylin
    Fletcher, Eden
    Curan, Megan
    Cipollone, Victoria
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2020, 33 (02): : 19 - 23
12345